Plus   Neg

Medivation Inc. (MDVN) Jumped To A New High On Phase 3 Study Results

Medivation Inc. (MDVN) and Astellas Pharma Inc. announced positive results from the Phase 3 PREVAIL trial of enzalutamide after the bell Tuesday.

Medivation gapped open dramatically higher Wednesday, but traded in a range throughout the session. The stock finished up by 8.51 at $84.29 on above average volume. Medivation rose above a 2-week range and set a new high for the year.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Follow RTT